Immunovaccine Inc. (TSX VENTURE:IMV), a clinical stage vaccine

development company focused on advancing its patented DepoVax? vaccine

adjuvanting platform and product candidates, today announced that it

has entered into a research collaboration with one of the world's

leading animal health companies to develop next generation companion

animal vaccines. Under terms of the collaboration, Immunovaccine will

combine multiple vaccine candidates provided by its research partner

with the company's proprietary DepoVax adjuvanting vaccine technology.

The resulting vaccine products, which are expected to deliver

long-lasting, single-dose protection against several of the most

common infectious diseases effecting dogs and cats, will then be

advanced through veterinary studies in several indications by

Immunovaccine's research partner.

DepoVax is a vaccine adjuvanting platform that has been demonstrated

to work effectively with a broad range of antigens. Once administered,

vaccine products that feature the technology create a unique depot

effect that attracts antigen-presenting cells to generate a rapid and

robust immune response. As a result, the next generation vaccine

candidates developed through this new collaboration have the potential

to drive a new standard of care in the vaccination of pets including

dogs and cats, offering the necessary protection in just a single


"This partnership is the latest development to highlight the

significant promise our DepoVax technology holds for delivering more

rapid, stronger and longer-lasting vaccines," said John Trizzino,

chief executive officer of Immunovaccine. "This extension of our

animal health partnering strategy also supports the advancement of our

work in human health by providing additional data regarding the immune

system response to a broader range of infectious disease agents."

In addition to animal health, Immunovaccine is also developing human

health vaccines for cancer therapy and infectious disease using the

DepoVax technology platform. The company has two therapeutic cancer

vaccines in clinical development; DPX-Survivac for ovarian cancer and

DPX-0907 for breast, ovarian, and prostate cancer, and has advanced

several candidates in infectious disease and biodefense through the

National Institutes of Health and other partnerships.

Today's agreement represents an expansion of Immunovaccine's

partnerships in animal health. The company's additional partnerships

in the area of animal health include its ongoing collaboration with

Pfizer Animal Health, which is focused on leveraging the DepoVax

technology to create advanced vaccines against infectious diseases for

multiple livestock indications.

There are currently more than 72 million pet dogs and 82 million pet

cats in U.S. households, according to the American Veterinary Medical

Association. There is a growing global demand for premium companion

animal vaccines that can be safely and easily administered. According

to a Global Industry Analysts report, the veterinary vaccine market is

projected to reach US$ 5.6 Billion by 2015. Growth in this market is

driven by an increasing number of pet owners demanding products that

enhance the health and well-being of their pets.

In additional corporate news, Immunovaccine has retained Vida

Communication to provide strategic public relations and investor

relations services, effective May 9, 2012. Under the terms of the

agreement, Immunovaccine will pay Vida Communication a monthly fee of

$10,000 for select strategic communication services. The initial

contract term is 12 months and commences immediately. Neither Vida

Communication nor any of its principals have an ownership interest,

directly or indirectly, in Immunovaccine or its securities, nor has

the company granted Vida Communication or its principals any rights to

acquire any such interests.

About Immunovaccine

Immunovaccine Inc. develops vaccines formulated in its vaccine

delivery platform for cancer therapy and infectious disease. The

company's DepoVax? platform is a patented lipid delivery system that

presents antigens plus adjuvant to the immune system for a prolonged

period and has the potential to enhance immune responses.

Immunovaccine has taken its platform technology and proprietary cancer

vaccine into Phase I human trials and has demonstrated its safety and

immunogenicity potential. The company is also capitalizing on the

broad potential of its delivery platform by creating new DepoVax-based

vaccines through multiple development collaborations. In addition to

the Company's human health vaccine strategy, it continues to capture

value from animal health vaccine applications. Pfizer Animal Health

has licensed the company's delivery technology platform to develop

vaccines for livestock. Connect at or

This press release contains forward-looking information under

applicable securities law. All information that addresses activities

or developments that we expect to occur in the future is

forward-looking information. Forward-looking statements are based on

the estimates and opinions of management on the date the statements

are made. However, they should not be regarded as a representation

that any of the plans will be achieved. Actual results may differ

materially from those set forth in this press release due to risks

affecting the Company, including access to capital, the successful

completion of clinical trials and receipt of all regulatory approvals.

Immunovaccine Inc. assumes no responsibility to update forward-looking

statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.